In this section
@article{van:2025:10.1183/2312508X.10027924,
author = {van, Manen MJG and Wu, Z and Molyneaux, PL and Wijsenbeek, MS},
doi = {10.1183/2312508X.10027924},
journal = {Ers Monograph},
pages = {206--224},
title = {Chronic cough and interstitial lung disease},
url = {http://dx.doi.org/10.1183/2312508X.10027924},
volume = {2025-December},
year = {2025}
}
TY - JOUR
AB - Cough is a common and burdensome symptom in interstitial lung disease (ILD), particularly IPF. It has a profound impact on quality of life and is associated with disease progression and poorer prognosis. This chapter outlines its epidemiology, pathophysiology, assessment and management. Underlying mechanisms include structural distortion, neurogenic inflammation and sensory pathway sensitisation, with comorbidities such as gastro-oesophageal reflux and obstructive sleep apnoea contributing to symptom burden. Evaluation of cough includes both subjective and objective measures. Management focuses on treatable traits, with speech and behavioural therapy showing benefit. Pharmacological options remain limited; however, opioids have demonstrated efficacy and new therapies are emerging. In non-IPF ILD, immunosuppressants may reduce cough, though evidence is mixed. Future research should aim to standardise outcome measures, enrich study populations and clarify whether cough acts as a driver or marker of disease progression.
AU - van,Manen MJG
AU - Wu,Z
AU - Molyneaux,PL
AU - Wijsenbeek,MS
DO - 10.1183/2312508X.10027924
EP - 224
PY - 2025///
SN - 2312-508X
SP - 206
TI - Chronic cough and interstitial lung disease
T2 - Ers Monograph
UR - http://dx.doi.org/10.1183/2312508X.10027924
VL - 2025-December
ER -
--tojpeg_1473680102479_x4.jpg)